Advanced liver cancer: Biologic combo ‘yields longest survival yet’
The median duration of response of one year is 'remarkable for liver cancer', a leading specialist says
The combination of atezolizumab and bevacizumab has yielded the longest overall survival ever seen in a phase 3 study of patients with advanced hepatocellular carcinoma (HCC), researchers say.
The IMbrave150 trial enrolled 501 patients with nonresectable, treatment-naive HCC.
